Treatment-related improvement in physical function varies with duration of rheumatoid arthritis: a pooled analysis of clinical trial results

被引:72
作者
Aletaha, D. [1 ]
Strand, V. [2 ]
Smolen, J. S. [3 ]
Ward, M. M. [4 ]
机构
[1] Med Univ Vienna, Dept Rheumatol, A-1090 Vienna, Austria
[2] Stanford Univ, Potola Vally, CA USA
[3] Hietzing Hosp, Dept Med 3, Vienna, Austria
[4] NIH, Natl Inst Arthritis & Musculoskeletal & Skin Dis, Bethesda, MD USA
关键词
D O I
10.1136/ard.2007.071415
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Physical function in rheumatoid arthritis ( RA) has reversible and irreversible components, and is typically assessed by the Health Assessment Questionnaire Disability Index (HAQ). Since irreversible components are expected to increase with longer duration of RA and reduce the ability for improvement in physical function, we analysed responsiveness of HAQ scores in patient populations with differing RA durations in randomised controlled trials (RCTs). Methods: Data from all RCTs published between 1980 and 2005 that reported changes from baseline in HAQ at 6 and/or 12 months were analysed. Treatments were grouped as "biologics'', or "traditional'' disease modifying antirheumatic drugs ( DMARDs), and "placebo''. We computed effect sizes of HAQ in each trial, and contrasted the association between these effects and duration of RA among treatment groups using regression models. Results: We identified 42 RCTs with complete data for the statistical models. The models indicate that discrimination of functional improvement between active drug groups and placebo is reduced in patients with a longer duration of RA (p = 0.02 for the change in discrimination over time). The placebo-adjusted HAQ responses decreased on average by 0.37 per year of RA duration. Conclusion: Responsiveness in HAQ scores is inversely associated with mean disease duration in RA. This impacts assessment of physical function, a key outcome measure in RCTs and practice, and impacts the ability to discriminate active treatment from placebo.
引用
收藏
页码:238 / 243
页数:6
相关论文
共 63 条
[1]   A RANDOMIZED DOUBLE-BLIND TRIAL OF CYCLOSPORINE AND AZATHIOPRINE IN REFRACTORY RHEUMATOID-ARTHRITIS [J].
AHERN, MJ ;
HARRISON, W ;
HOLLINGSWORTH, P ;
BRADLEY, J ;
LAING, B ;
BAYLISS, C .
AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 1991, 21 (06) :844-849
[2]   Duration of rheumatoid arthritis influences the degree of functional improvement in clinical trials [J].
Aletaha, D ;
Ward, MM .
ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (02) :227-233
[3]   Measuring function in rheumatoid arthritis - Identifying reversible and irreversible components [J].
Aletaha, Daniel ;
Smolen, Josef ;
Ward, Michael M. .
ARTHRITIS AND RHEUMATISM, 2006, 54 (09) :2784-2792
[4]  
Bao CD, 2003, CHINESE MED J-PEKING, V116, P1228
[5]   A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis [J].
Bathon, JM ;
Martin, RW ;
Fleischmann, RM ;
Tesser, JR ;
Schiff, MH ;
Keystone, EC ;
Genovese, MC ;
Wasko, MC ;
Moreland, LW ;
Weaver, AL ;
Markenson, J ;
Finck, BK .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (22) :1586-1593
[6]   Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis [J].
Boers, M ;
Verhoeven, AC ;
Markusse, HM ;
vandeLaar, MAFJ ;
Westhovens, R ;
vanDenderen, JC ;
vanZeben, D ;
Dijkmans, BAC ;
Peeters, AJ ;
Jacobs, P ;
vandenBrink, HR ;
Schouten, HJA ;
vanderHeijde, DMFM ;
Boonen, A ;
vanderLinden, S .
LANCET, 1997, 350 (9074) :309-318
[7]   AURANOFIN THERAPY AND QUALITY-OF-LIFE IN PATIENTS WITH RHEUMATOID-ARTHRITIS - RESULTS OF A MULTICENTER TRIAL [J].
BOMBARDIER, C ;
WARE, J ;
RUSSELL, IJ ;
LARSON, M ;
CHALMERS, A ;
READ, JL .
AMERICAN JOURNAL OF MEDICINE, 1986, 81 (04) :565-578
[8]   Association between baseline radiographic damage and improvement in physical function after treatment of patients with rheumatoid arthritis [J].
Breedveld, FC ;
Han, C ;
Bala, M ;
van der Heijde, D ;
Baker, D ;
Kavanaugh, AF ;
Maini, RN ;
Lipsky, PE .
ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (01) :52-55
[9]   The PREMIER study - A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment [J].
Breedveld, FC ;
Weisman, MH ;
Kavanaugh, AF ;
Cohen, SB ;
Pavelka, K ;
van Vollenhoven, R ;
Sharp, J ;
Perez, JL ;
Spencer-Green, GT .
ARTHRITIS AND RHEUMATISM, 2006, 54 (01) :26-37
[10]  
Bresnihan B, 1998, ARTHRITIS RHEUM, V41, P2196, DOI 10.1002/1529-0131(199812)41:12<2196::AID-ART15>3.0.CO